

**Public and Private Insurance Forum Agenda**  
**Thursday, January 24, 2019, 7:30am-6:30pm**  
**Westin Harbour Castle, Toronto, Ontario**

<p><b>Kelly Grover</b>, President &amp; CEO, Cystic Fibrosis Canada</p>	<p>Welcome</p>
<p><b>Dr. John Wallenburg</b>, Chief Scientific Officer, Cystic Fibrosis Canada</p>	<p>Introduction to cystic fibrosis, the development pipeline and access issues, what CFC is doing to address these issues through research and clinical investments.</p>
<p><b>Dr. Timothy Caulfield</b>, Canada Research Chair, Health Law and Policy, Author of <i>Is Gwyneth Paltrow Wrong About Everything?</i></p>	<p><b>Keynote Speaker:</b> Access to precision medicines present drug access opportunities and challenges. Our current regulatory and reimbursement systems were not built with these medicines in mind. What are some of the legal and ethical issues we need to consider in order to improve access to precision medicines in Canada?</p>
<p><b>Dr. Felix Ratjen</b>, Division Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Senior Scientist at the Research Institute in the Translational Medicine research program, Co-leader of CF centre at SickKids and Medical Director of the Clinical Research Unit</p>	<p>The power of precision medicines and the potential that the <a href="#">Cystic Fibrosis Individualized Therapy Program (CFIT)</a> has to help predict which medicines work in which individuals, how the program may help streamline our Health Technology Assessment processes, help manage public drug program costs, and how public and private insurers may get involved now and in the future.</p>
<p><b>Dr. Christine Bear</b>, Senior Scientist, Molecular Medicine, Professor, Physiology, University of Toronto</p>	
<p><b>Pamela Fralick</b>, President, Innovative Medicines Canada</p>	<p>From a pharmaceutical industry perspective, what roles do precision medicines play in managing the health and wellness of Canadians with rare diseases? How might a program like CFIT impact access to precision medicines in Canada, including Health Technology Assessment, pricing and reimbursement?</p>

**Karen Voin**, VP Group Benefits and Anti-Fraud, Canadian Life and Health Insurance Association

From a private health insurance perspective, what roles do precision medicines play in managing the health and wellness of Canadians with rare diseases? How might a program like CFIT impact access to precision medicines in Canada, including Health Technology Assessment, pricing and reimbursement?

**Dan Berty**, Executive Director, Canadian Drug Insurance Pooling Corporation

Drug pooling in Canada: how it works and how it doesn't. What role, if any, does pooling play access to precision medicines for rare diseases? Is there a role for programs like CFIT to play in pooling?

**Heather Logan**, Vice-President, Pharmaceutical Reviews, Canadian Agency on Drugs and Technologies in Health

Panel Discussion: Ali Imran, Manager, pCPA; PMPRB(TBD); provincial drug program manager (TBD). From a public payer perspective, what roles do precision medicines play in managing the health and wellness of Canadians with rare diseases? How might a program like CFIT impact access to precision medicines in Canada, including Health Technology Assessment, pricing and reimbursement?

**Kim Steele**, Director, Government and Community Relations, Cystic Fibrosis Canada

Open discussion: what can we do collectively to maximize the clinical and budgetary benefits that personalized and precision medicines bring? How can we work together to improve access to personalized and precision medicines? How can we incorporate programs like CFIT in these strategies?